Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Gains from Investment Securities: 2019-2025

Historic Gains from Investment Securities for BridgeBio Pharma (BBIO) over the last 7 years, with Sep 2025 value amounting to $1.3 million.

  • BridgeBio Pharma's Gains from Investment Securities fell 7.69% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.2 million, marking a year-over-year decrease of 5.50%. This contributed to the annual value of $7.5 million for FY2024, which is 9.39% up from last year.
  • As of Q3 2025, BridgeBio Pharma's Gains from Investment Securities stood at $1.3 million, which was down 10.66% from $1.5 million recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's Gains from Investment Securities ranged from a high of $10.2 million in Q2 2022 and a low of -$3.6 million during Q4 2022.
  • Its 3-year average for Gains from Investment Securities is $1.9 million, with a median of $1.5 million in 2025.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first crashed by 1,674.35% in 2022, then spiked by 4,560.71% in 2023.
  • Over the past 5 years, BridgeBio Pharma's Gains from Investment Securities (Quarterly) stood at $230,000 in 2021, then tumbled by 1,674.35% to -$3.6 million in 2022, then surged by 170.56% to $2.6 million in 2023, then crashed by 45.05% to $1.4 million in 2024, then decreased by 7.69% to $1.3 million in 2025.
  • Its Gains from Investment Securities stands at $1.3 million for Q3 2025, versus $1.5 million for Q2 2025 and $4.0 million for Q1 2025.